Skip to main content
Dimitrios Tzachanis, MD, Oncology, La Jolla, CA, UC San Diego Medical Center - Hillcrest

DimitriosTzachanisMD

Oncology La Jolla, CA

Physician

Dr. Tzachanis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Tzachanis' full profile

Already have an account?

Education & Training

  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
  • Dartmouth-Hitchcock/Mary Hitchcock Memorial Hospital
    Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 2000 - 2003
  • Aristotle University of Thessaloniki School of Medicine
    Aristotle University of Thessaloniki School of MedicineClass of 1997

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2012 - 2024
  • MA State Medical License
    MA State Medical License 2003 - 2018
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
    Dimitrios Tzachanis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
    Dimitrios Tzachanis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematolo...
    Dimitrios Tzachanis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Protmune, a Next-Generation Graft for GvHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: 1-Year Safety and Efficacy Phase 1 DataClinically Relevant Abs... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • UC San Diego Health Begins Treating Multiple Myeloma with CAR T-cell Therapy
    UC San Diego Health Begins Treating Multiple Myeloma with CAR T-cell TherapyJune 3rd, 2021
  • Dr. Tzachanis on Data with Lisocabtagene Maraleucel in Lymphoma
    Dr. Tzachanis on Data with Lisocabtagene Maraleucel in LymphomaFebruary 28th, 2020
  • Cancer Cell Therapy Success Grows, but Hospitals Struggle with Cost
    Cancer Cell Therapy Success Grows, but Hospitals Struggle with CostOctober 4th, 2019

Professional Memberships

Hospital Affiliations